Prøve GULL - Gratis
How Seed Funding is Driving Indian Pharma Startups
Bio Spectrum
|BioSpectrum India Nov 2024
For pharmaceutical businesses in India, seed capital is more than just a financial boost; it is an essential component of long-term success. In order to draw in future investors, it assists businesses in innovating, scaling up, and overcoming regulatory obstacles. This has a beneficial knock-on impact and helps to create a healthier and more inventive future for India's health industry. Let's explore further.

Pharmaceutical startups looking for seed funding to turn their ideas into reality and develop solutions that improve patients’ lives benefit greatly from early-stage capital. Such capital would be spent on innovation, breakthroughs in drug discovery, AI-related health technologies, and personalised medicine. For example, the majority of India’s healthcare startups are focused on creating tech solutions that drive efficiency in the supply chain or improve patient outcomes. These startups have utilised seed funding to enhance their offerings, streamline operations, and deliver better healthcare solutions.
Seed funding plays a pivotal role in this growth trajectory, serving as the essential capital that ignites innovation and propels startups forward. For many emerging companies, access to early-stage capital is crucial for developing their proof of concept (POC) and attracting top talent. In a highly competitive market, having the right resources enables startups to innovate rapidly and respond to the evolving needs of the healthcare sector. As artificial intelligence (AI) and other advanced technologies reshape the healthcare industry, startups face constant pressure to adapt and enhance their offerings. This necessity for continuous innovation underscores the importance of securing seed funding, as it allows companies to invest in research and development (R&D), refine their technologies, and launch new products or services without the immediate burden of achieving profitability.
Beginning of Innovation
Denne historien er fra BioSpectrum India Nov 2024-utgaven av Bio Spectrum.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum
India's Pharma Reforms Target Global Credibility
The Indian government has introduced several measures to simplify drug approvals and support innovation.
9 mins
October 2025

Bio Spectrum
How Waste Management Strategies Can Transform Indian Pharma Manufacturing
Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.
7 mins
October 2025

Bio Spectrum
IASST synthesises new compound to combat aggressive breast cancer
A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.
1 min
October 2025
Bio Spectrum
DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.
1 min
October 2025

Bio Spectrum
WHO unveils updated guideline on HIV service delivery
WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.
1 min
October 2025
Bio Spectrum
Scientists in Kolkata explore therapeutic potential of accessory proteins
A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.
1 min
October 2025

Bio Spectrum
US FDA advances rare disease drug development
The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
1 min
October 2025
Bio Spectrum
WHO updates list of essential medicines to include key cancer, diabetes treatments
The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.
1 min
October 2025
Bio Spectrum
Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification
Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.
1 min
October 2025
Bio Spectrum
Aodh Lifesciences gets support from TDB to redefine pneumonia treatment
The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).
1 min
October 2025
Listen
Translate
Change font size